ATAI Life Sciences is a clinical-stage biopharmaceutical company focusing on the development of therapeutic solutions for various mental health disorders including treatment-resistant depression (TRD). ATAI has a plethora of pipelines including COMP360 psilocybin for TRD in Phase 2 clinical trial, PCN-101, a subcutaneous formulation of R-ketamine for TRD, GRX-917, a deuterated version of Etifoxine, DMX-1002 ibogaine and ..read more

Anebulo Pharmaceuticals, Inc., is a clinical-stage biotechnology company, developing therapeutic compounds for the management of acute cannabinoid intoxication (ACI) and substance addiction. The lead asset, ANEB-001 is a small molecule cannabinoid receptor antagonist being investigated as a specific anti-dote for ACI. To date, no specific treatment or drugs are available for ACI, which remains a ..read more

Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell therapies with a therapeutic focus on immuno-oncology. Kiromic Biopharma is the only cell therapy company combining genetically edited Gamma Delta CAR-T (GD CAR-T) cells with proprietary targeting technology to address solid malignancies ..read more

ImmunoGen Inc. is a clinical-stage biotechnology company focusing on the development of antibody-drug conjugate (ADC) as a treatment for cancer. The lead pipeline is mirvetuximab soravtansine, an inhibitor of folate-receptor alpha (FRa). The pipeline is in Phase III clinical trial to investigate the safety and efficacy against platinum-resistant ovarian cancer. The next important pipeline is ..read more

BeyondSpring Inc. is an early-stage clinical trial biopharmaceutical company developing immuno-oncology therapies (anti-cancer drugs). The main pipeline is Plinabulin, an anti-cancer drug that is being investigated as a combined therapy with other biologics such as Nivolumab, a PD-1 antibody for the treatment of NSCLC, Ipilimumab a CTLA-4 antibody for the treatment of small cell lung ..read more

Formerly known as Impel Neuropharma Inc, Impel Pharmaceuticals Inc is a commercial-stage biopharmaceutical company, developing and commercializing treatments for central nervous system disorders in the United States. The approved asset is Trudhesa, an upper nasal formulation of dihydroergotamine for the treatment of migraine. IMPL is now developing INP105 (upper nasal formulation of Olanzepine) as a ..read more

Aquestive Therapeutics, Inc is a clinical and commercial-stage pharmaceutical company focusing on the development and commercialization of various therapeutic drugs to meet various unmet needs in the United States and across the globe.  AQST has focused on the development of orally-soluble film as a delivery platform for several drugs to treat various medical conditions. The ..read more